US Neurodegeneration Epidemiology
Overview
The United States faces a significant and growing burden from neurodegenerative diseases. Aging demographics, improved diagnostic capabilities, and better disease recognition drive increasing prevalence across Alzheimer's disease, Parkinson's disease, and related disorders. This page provides detailed epidemiological data for major neurodegenerative conditions affecting the US population.
Alzheimer's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 65-74 years | ~3% | ~1.1 million |
| 75-84 years | ~13% | ~2.8 million |
| 85+ years | ~35% | ~3.3 million |
| Total (65+) | ~11% (1 in 9) | ~7.2 million |
| Younger-onset (<65) | ~110 per 100,000 | ~200,000 |
Key Statistics:
- 74% of Alzheimer's patients are age 75 or older
- Nearly two-thirds are women (reflecting longer life expectancy)
- 1 in 9 people age 65 and older has Alzheimer's disease
Projections
| Year | Projected Prevalence | Change |
|------|---------------------|--------|
| 2025 | 7.2 million | Baseline |
| 2030 | 8.5 million | +18% |
| 2040 | 10.3 million | +43% |
| 2050 | 12.7 million | +76% |
The projected 76% increase from 2025 to 2050 reflects the aging of baby boomers into high-risk age groups.
Regional Distribution
...US Neurodegeneration Epidemiology
Overview
The United States faces a significant and growing burden from neurodegenerative diseases. Aging demographics, improved diagnostic capabilities, and better disease recognition drive increasing prevalence across Alzheimer's disease, Parkinson's disease, and related disorders. This page provides detailed epidemiological data for major neurodegenerative conditions affecting the US population.
Alzheimer's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 65-74 years | ~3% | ~1.1 million |
| 75-84 years | ~13% | ~2.8 million |
| 85+ years | ~35% | ~3.3 million |
| Total (65+) | ~11% (1 in 9) | ~7.2 million |
| Younger-onset (<65) | ~110 per 100,000 | ~200,000 |
Key Statistics:
- 74% of Alzheimer's patients are age 75 or older
- Nearly two-thirds are women (reflecting longer life expectancy)
- 1 in 9 people age 65 and older has Alzheimer's disease
Projections
| Year | Projected Prevalence | Change |
|------|---------------------|--------|
| 2025 | 7.2 million | Baseline |
| 2030 | 8.5 million | +18% |
| 2040 | 10.3 million | +43% |
| 2050 | 12.7 million | +76% |
The projected 76% increase from 2025 to 2050 reflects the aging of baby boomers into high-risk age groups.
Regional Distribution
- Northeast: Higher proportion of elderly population; older demographic structure
- South: Highest absolute numbers due to large population; growing elderly population
- Midwest: Average prevalence; stable demographic patterns
- West: Growing elderly population; significant increase projected
Economic Burden
| Cost Category | Annual Amount |
|---------------|---------------|
| Total direct costs | ~$360 billion |
| Informal caregiving | ~$340 billion |
| Total economic burden | ~$700 billion |
| Per-patient annual cost | ~$24,000 |
Parkinson's Disease
Prevalence (2025)
| Age Group | Prevalence Rate | Number Affected |
|-----------|-----------------|-----------------|
| 50-59 years | ~0.5% | ~300,000 |
| 60-69 years | ~1.0% | ~500,000 |
| 70-79 years | ~2.5% | ~700,000 |
| 80+ years | ~3.5% | ~500,000 |
| Total | ~1-2% (65+) | ~1.5 million |
Note: An estimated 50-90% of cases go undiagnosed, suggesting true prevalence may be 1.5-2x higher.
Projections
| Year | Projected Prevalence | Notes |
|------|---------------------|-------|
| 2025 | 1.5 million | Current estimate |
| 2030 | 1.8 million | +20% |
| 2040 | 2.4 million | +60% |
| 2050 | 3.0 million | +100% |
Regional Distribution
Parkinson's shows higher prevalence in:
- Industrial Midwest (environmental exposure history)
- Rural areas (pesticide exposure correlation)
- Northeast (aging population)
Economic Burden
| Cost Category | Annual Amount |
|---------------|---------------|
| Direct medical costs | ~$26 billion |
| Non-medical costs | ~$26 billion |
| Total (US) | ~$52 billion |
| Per-patient annual cost | ~$26,000 |
Amyotrophic Lateral Sclerosis (ALS)
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Total prevalence | ~30,000-50,000 |
| Annual new cases | ~5,000-6,000 |
| Annual deaths | ~5,000-6,000 |
| Median survival | 2-5 years |
Demographics:
- Mean age at onset: 55 years
- 60% male
- 90-95% sporadic, 5-10% familial
Economic Burden
| Cost Category | Amount |
|---------------|--------|
| Direct medical | ~$1.5 billion/year |
| Equipment & caregiving | ~$4.5 billion/year |
| Lost productivity | ~$400 million/year |
| Total (US) | ~$6 billion/year |
| Per-patient lifetime cost | ~$1.5-2.5 million |
Frontotemporal Dementia (FTD)
Prevalence (2025)
| Variant | Estimated Cases |
|---------|-----------------|
| Behavioral variant FTD | ~30,000-40,000 |
| Primary progressive aphasia | ~10,000-15,000 |
| Total FTD | ~50,000-60,000 |
Note: FTD is significantly underdiagnosed; true prevalence may be 2-3x higher. FTD is a leading cause of dementia under age 65.
Age Distribution
- Mean age at onset: 50-60 years (earlier than AD)
- 30% have family history
- Slight male predominance
Huntington's Disease
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Gene carriers (at risk) | ~200,000-250,000 |
| Manifest HD patients | ~40,000-50,000 |
| Juvenile HD (<20 years) | ~5-10% of cases |
Economic Burden
| Category | Amount |
|----------|--------|
| Direct costs | ~$12,000/year |
| Informal care | ~$30,000/year |
| Lost productivity | ~$30,000/year |
| Total annual | ~$72,000/patient |
Progressive Supranuclear Palsy (PSP)
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Estimated prevalence | ~20,000-30,000 |
| Underdiagnosis factor | ~3-5x |
| True prevalence | ~60,000-100,000 |
| Mean age at onset | ~63 years |
Multiple System Atrophy (MSA)
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Estimated prevalence | ~10,000-20,000 |
| Mean age at onset | ~53-60 years |
| Slight male predominance | 1.5:1 |
Corticobasal Syndrome (CBS)
Prevalence (2025)
| Metric | Value |
|--------|-------|
| Estimated prevalence | ~5,000-10,000 |
| Mean age at onset | ~60-70 years |
| Underrecognition | Significant |
Summary: US Neurodegeneration Burden
| Disease | Prevalence (2025) | Projected 2050 | Annual Economic Cost |
|---------|-------------------|----------------|---------------------|
| Alzheimer's Disease | 7.2 million | 12.7 million | ~$700 billion |
| Parkinson's Disease | 1.5 million | 3.0 million | ~$52 billion |
| ALS | 30,000-50,000 | Stable | ~$6 billion |
| FTD | 50,000-60,000 | 100,000+ | ~$15 billion |
| Huntington's Disease | 40,000-50,000 | Stable | ~$3 billion |
| PSP | 60,000-100,000* | — | ~$5 billion |
| MSA | 10,000-20,000 | — | ~$2 billion |
*True prevalence accounting for underdiagnosis
Cross-Links
- [Neurodegeneration Impact Measures](/diseases/neurodegeneration-impact-measures)
- [Epidemiology of Neurodegenerative Diseases](/diseases/epidemiology-neurodegenerative-diseases)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD](/diseases/frontotemporal-dementia)
References
[Alzheimer's Association 2025 Facts and Figures Report](https://www.alz.org/alzheimers-dementia/facts-figures)
[Parkinson's Foundation Prevalence Estimates](https://www.parkinson.org/)
[CDC ALS Registry Data](https://www.cdc.gov/als/)
[GBD 2024 Neurological Disorders Study](https://www.thelancet.com/journals/lancet/neurology)